Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice

Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered either prior to the appearance of disease phenotypes or in advanced stages of disease in the YAC128 m...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JCI Insight
Autori principali: Garcia-Miralles, Marta, Geva, Michal, Tan, Jing Ying, Yusof, Nur Amirah Binte Mohammad, Cha, Yoonjeong, Kusko, Rebecca, Tan, Liang Juin, Xu, Xiaohong, Grossman, Iris, Orbach, Aric, Hayden, Michael R., Pouladi, Mahmoud A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5752291/
https://ncbi.nlm.nih.gov/pubmed/29212949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.95665
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi